Ignite Creation Date:
2024-05-05 @ 11:38 AM
Last Modification Date:
2024-10-26 @ 9:11 AM
Study NCT ID:
NCT00096122
Status:
COMPLETED
Last Update Posted:
2014-05-26
First Post:
2004-11-09
Brief Title:
Idarubicin Cytarabine and Tipifarnib in Treating Patients With Newly Diagnosed Myelodysplastic Syndromes or Acute Myeloid Leukemia
Sponsor:
National Cancer Institute NCI
Organization:
National Cancer Institute NCI
Conditions & Keywords Data
Conditions:
| Name |
|---|
| Adult Acute Basophilic Leukemia |
| Adult Acute Eosinophilic Leukemia |
| Adult Acute Megakaryoblastic Leukemia M7 |
| Adult Acute Minimally Differentiated Myeloid Leukemia M0 |
| Adult Acute Monoblastic Leukemia M5a |
| Adult Acute Monocytic Leukemia M5b |
| Adult Acute Myeloblastic Leukemia With Maturation M2 |
| Adult Acute Myeloblastic Leukemia Without Maturation M1 |
| Adult Acute Myeloid Leukemia With 11q23 MLL Abnormalities |
| Adult Acute Myeloid Leukemia With Inv16p13q22 |
| Adult Acute Myeloid Leukemia With t1616p13q22 |
| Adult Acute Myeloid Leukemia With t821q22q22 |
| Adult Acute Myelomonocytic Leukemia M4 |
| Adult Erythroleukemia M6a |
| Adult Pure Erythroid Leukemia M6b |
| Childhood Myelodysplastic Syndromes |
| Chronic Myelomonocytic Leukemia |
| de Novo Myelodysplastic Syndromes |
| Refractory Anemia With Excess Blasts |
| Refractory Anemia With Excess Blasts in Transformation |
| Secondary Acute Myeloid Leukemia |
| Secondary Myelodysplastic Syndromes |
| Untreated Adult Acute Myeloid Leukemia |
Keywords: